Introduction
Multidrug resistant bacteria account for a substantial percentage of nosocomial infections and represent a serious threat to human health. In addition, their recalcitrance to commonly used drugs poses a significant therapeutic challenge. Such bacteria include established threat organisms such as the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) as well as emerging pathogens such as carbapenem-resistant K. pneumoniae CRKP and the New Delhi metallo-blactamase containing Enterobacteriaceae [1] [2] [3] [4] .
Inappropriate or unnecessary antibiotic prescriptions, the excessive use of antibiotics in the agricultural and livestock industries, and the lack of patient adherence to full antibiotic regimens, all of which select for resistant bacteria, appear to be the key contributors to the emergence of antibiotic resistance. Because of the increasing threat of multidrug resistant pathogens and the continuing evolution of resistance, there is a pressing need to develop new antibacterial therapies.
Beginning with the discovery of penicillin in 1929, natural products have been the main source of new antibacterial drugs and have revolutionized the treatment of infectious diseases. In the past 80 years numerous classes of natural product antibacterials ( Figure 1 ) have been discovered. Natural products and their analogs continue to play a prominent role in medicine, accounting for two-thirds of new antibacterial therapies approved from 1980 to 2010 [5] as well as several antibacterials currently in clinical trials (Table 1, Figure 2A ). The efficacy of natural products as antibacterial agents likely stems from the fact that they have been honed by evolutionary processes to be bioactive, thereby giving the producing organisms a selective advantage in the environment. In spite of the promise of natural products, the discovery and development of new antibacterial drugs by large pharmaceutical companies has waned over the last two decades. Companies with active antibacterial discovery programs have gradually diminished these efforts [6] . This de-emphasis on industrial development of new antibacterials may be due to the perceptions that the market is saturated, that new drug targets are scarce, and that obtaining regulatory approval is increasingly difficult [7] . This gloomy reality is often described as the 'end of the antibiotic era'. Interestingly, this landscape has generated a vacuum in which smaller biotechnology firms can innovate and compete. For example, in 1995, the 10 largest pharmaceutical companies had only 3 antibacterials in clinical development compared to 17 compounds being developed by the biotechnology industry [8, 9] . However, these efforts have only occasionally yielded novel classes of antibacterials. Rather, the majority of new drugs have arisen by alteration of existing drugs to improve efficacy, reduce resistance, and minimize toxicity [7] .
Discovery and development of new antibacterial agents is undergoing a renaissance brought on by the confluence of diverse fields and expertise; and once again natural products are coming to the forefront. The speed with which new antibacterial drug targets and mechanisms of action are being discovered is likely to increase due to improvements in existing methodologies and the introduction of new technologies. An improved understanding of the phenotypic determinants of bacterial virulence and pathogenicity, including drug efflux, biofilm formation, and quorum sensing, is setting the stage for development Natural product antibacterials Bologa et al. 679 Prevalence of natural versus synthetic classes of FDA approved antibacterials. Natural products and their derivatives are shown in pink and red and synthetics are shown in white and gray. The year of discovery of the first representative of each class is indicated in parentheses. Sizes of pie chart portions correspond to the number of compounds from each class among the 210 antibacterials approved to date. This article highlights some of the recent advances as well as the emerging challenges of natural product antibacterial drug discovery and development. Natural product drug discovery, slowly marginalized by the biopharmaceutical industry over the last 20 years, is poised to make a comeback. These efforts are supported by new legislative and funding initiatives to spur development of antibacterial discovery programs and thereby ensure a continued supply of the new drugs needed to combat today's emerging infectious disease threats.
Advances in bioactivity-guided discovery
New targets
Both academic and industrial settings have identified a list of targets that have been newly discovered, rediscovered, or revitalized. Inhibition of the synthesis of bacterial peptidoglycan has been recognized for over 50 years as fertile ground for antibacterial discovery. Initially, screening of natural products for inhibition of bacterial growth detected many chemical classes of antibiotics whose mechanisms of action were eventually determined [11, 12] . The filamentous temperature-sensitive mutant Z (FtsZ), a conserved protein essential for bacterial cell division and a homolog of eukaryotic tubulin, is a recently identified potential drug target [13] . Recent evidence that the plant-derived antibacterial berberine can also act as an antifilarial by targeting FtsZ in Wolbachia, a bacterial symbiont of the nematode Onchocerca volvulus, is also intriguing [14] .
Inhibiting translation via the therapeutically unexploited (with respect to natural products) A-site of the bacterial ribosome is a potentially promising new avenue for antibacterial therapy. Bottromycins, modified peptides that bind to the A-site and are active against VancomycinResistant Enterococci (VRE), have recently been the target of bioengineering studies aimed at lead optimization [15] .
Recent work on pyridomycin, a compound with antimycobacterial activity produced by Dactylosporangium fulvum, illustrates the power of genomics in determining mechanism of action. Examination of pyridomycin-resistant mutants of Mycobacterium tuberculosis by whole-genome sequencing and subsequent genetic confirmation identified the NADH-dependent enoyl-acyl carrier protein reductase InhA as the principal target of pyridomycin. Structural studies of InhA identified it as a new druggable target. The same study also provided evidence for the increased susceptibility of isoniazid-resistant mycobacterial clinical isolates to pyridomycin [16] .
Antimetabolites, natural mimics of essential metabolites such as coenzymes, are also considered lead structures for the development of new antibiotics. Roseoflavin, an antimetabolite of riboflavin (vitamin B2), identified in Streptomyces davawensis, inhibits Listeria monocytogenes at very low concentrations [17] . Similarly, the natural product CJ-15,801, which shares structural similarity with pantothenic acid (the vitamin precursor of coenzyme A (CoA)), and therefore likely blocks a step in CoA biosynthesis or utilization, was found to inhibit S. aureus [18] .
New assays
Advances in our understanding of bacterial cell physiology shed light on a series of pathways and phenotypes that may serve as attractive targets for antibacterial drug discovery. A common theme is an attempt to dissect at the molecular level the social (intercellular) interactions in both synthetic and natural bacterial populations. It is thought that these interactions are important determinants of antibiotic resistance and tolerance [19 ] . A few examples illustrate the importance of social interactions The key elements, tools, and outcomes of biosynthesis-guided natural products discovery using both natural and engineered biological systems.
in natural antibiotic discovery and the diversity of antagonistic behaviors among bacteria 'in the wild'. A screen of approximately 35,000 possible mutual interactions among Vibrionaceae ocean isolates showed a direct correlation between genotypic clusters that participate in natural antibiotic production and resistance and cohesive habitat association. Genetic analysis of these populations indicates that a small proportion of the population are antibiotic producers while the majority are resistant. These results support the idea that conspecifics interact cooperatively and that natural antibiotics are used as signal-mediators for competition with other species rather than a means for individual genotypes to achieve dominance [20 ] .
Studies of the diversity of natural products made by bacterial communities in soil-associated and plant-associated environments and their activity patterns against coexisting microorganisms have revealed multiple activities beyond the historical perception of these compounds as weapons used in microbial conflicts [21] . Many biological processes are regulated by antibiotics, including changes in development that promote survival in adverse conditions, virulence toward host plants, and modulation of multi-trophic interactions. These recent studies challenge us to develop innovative phenotype-based antibacterial assays that are responsive to the dynamic nature of microbial communities. We highlight four such assay platforms that utilize natural products as lead compounds.
(1) Inhibition of drug efflux using natural product efflux pump inhibitors (EPIs) in combination with other drugs has emerged as a potentially fruitful avenue for antibacterial therapy. Both novel and previously known natural products that are active against several bacterial efflux systems have recently been reported [22, 23] . The concept of increasing the efficacy of antibacterials by employing EPIs is appealing. However clinical implementation is hampered both by the needs for improved screening methodologies and for a more detailed understanding of drug efflux mechanisms. [24] . (2) Quorum sensing inhibition (QSI) has been proposed as an attractive way to combat pathogens since QS systems are known to be key regulators of virulence factor production. QSI may target the synthesis of QS signal molecules, interfere with signal secretion or degradation, inhibit binding of QS signal molecules to their receptors, or inhibit downstream signal transduction cascades. Research on identifying natural products QSIs has recently intensified both conceptually and with respect to the number of available lead chemotypes. For example, natural product honaucins A-C isolated from the cyanobacterium Leptolyngbya crossbyana exhibited potent inhibition of both bioluminescence, a QS-dependent phenotype, in Vibrio harveyi BB120 and lipopolysaccharide-stimulated nitric oxide production in murine macrophages [25] . Bioassay-guided fractionation of garlic extracts also led to the identification of ajoene, a sulfur-containing compound, as a QSI are active against P. [28 ] . Immuno-therapeutics are also a potential means of antibacterial therapy as illustrated by the recent report of raising human monoclonal antibodies and polyclonal sera against the common bacterial surface polysaccharide, poly-b-1,6-N-acetylglucosamine (PNAG) [29] .
Advances in biosynthesis-guided discovery
Synthetic and biosynthetic chemists endeavor to produce natural products and their analogs cheaply and efficiently. Understanding the details of natural product biosynthetic pathways is key to accomplishing this goal. To date 700 bacterial and fungal natural product biosynthetic gene clusters, many of which encode antibacterial compounds, have been cloned and sequenced. This has lead to functional elucidation of many of the biosynthetic steps in common natural product biosynthetic modes: type I [30] and type II polyketide synthases (PKS-I and PKS-II, respectively), non-ribosomal peptide synthetases (NRPS) [31] , and ribosomal peptide (RiPP) biosynthetic systems [32] . These studies imply that natural product pathways are modularly organized and have been combinatorially rearranged through evolution to produce the staggering array of observed structures. The diversity-oriented nature of these pathways implies that many new enzymatic activities, biosynthetic pathways, and biosynthetic paradigms remain to be discovered. Figure 3 summarizes the key elements, tools, and outcomes of biosynthesisguided natural product discovery in both natural and engineered biological systems.
Our understanding of natural product biosynthesis allows combined bioengineering and chemical approaches for constructing natural product analogs. Both in vivo unnatural amino acid mutagenesis and chemoenzymatic synthesis strategies were recently used to create unnatural amino acid-bearing analogs of ribosomal peptides cyanobactin [33] , an inhibitor of drug efflux, and lacticin 481 [34] , an antibacterial compound targeting peptidoglycan biosynthesis. In the latter case, analogs with improved potency were identified. Precursor-directed biosynthesis, in which synthetic compounds mimicking a biosynthetic intermediate are fed to a producing organism, continues to be an effective strategy for generating natural product analogs. This strategy was recently used for production of an equipotent erythromycin analog bearing an easily derivatizable alkyne functional group [35] . The ability to biosynthetically install such 'chemical handles' into natural products will be invaluable in medicinal chemistry and probe development for mechanism of action studies and high throughput screening.
Our extensive knowledge of natural product structure, bioactivity, and biosynthesis is now being applied in a holistic manner to discover new bioactive natural products. StreptomeDB [36] , a database that integrates from literature mining these various types of information on >2400 bioactive natural products from Streptomyces species, facilitates in silico screening for new bioactivities. BioMAP [37] , an experimentally obtained database of activity profiles of a panel of natural product structural classes against clinically relevant bacterial strains, establishes bioactivity fingerprints useful for identifying new classes of antibacterial compounds in crude extracts.
It is apparent from analysis of microbial genome sequence data that thousands of unstudied natural product gene clusters are encoded in microbial genomes. The ability to reliably identify these gene clusters through sequence analysis and to accurately predict the structures of encoded compounds from sequence data may eventually enable rapid in silico screening for novel natural product biosynthetic capabilities. antiSMASH [38 ] , a software package designed for this purpose, is a move in this direction. However, because many natural product gene clusters are 'cryptic', or transcriptionally silent in particular culture conditions, experimental techniques such as transcriptomics combined with methods for activating cryptic clusters such as variation of culture conditions, co-culture with other microbes, disruption or overexpression of cluster-specific regulatory proteins (CSRs), and insertion of strong constitutive promoters [39] will be required to reap the full benefits of in silico predictions. Nevertheless, we expect rapid advances in this area in the near future.
The vast majority of microbes are not amenable to laboratory cell culture, leaving a huge portion of natural product diversity unexplorable by traditional culture-dependent methods. Recently metagenomics has been used to discover new antibacterial compounds tetarimycin [40] and fasamycin, an inhibitor of the fatty acid biosynthesis protein FabF [41] . In these studies, cosmid libraries were constructed from soil environmental DNA and heterologously expressed in Streptomyces albus. The transformants were then screened for antibacterial activity. Cosmids from active clones were sequenced and the structures of the encoded compounds were determined by NMR and X-ray crystallography. This approach holds promise for accessing compounds from uncultivable organisms. However, limitations of this approach lie in the fact that many gene clusters are not active when heterologously expressed and many natural product gene clusters are too large to be captured intact on a single cosmid.
The large volume of data linking organisms with the natural products they produce is beginning to reveal that natural product biosynthesis is unevenly distributed in nature. A recent study on Cyanobacteria correlated natural product biosynthesis with only a few clades within the phylum [42] . Such analyses can facilitate phylogenetics-based bioprospecting. Phylogenetic analysis of individual natural product gene amplicons can also be used to predict the presence of specific biosynthetic subclasses and to differentiate novel versus known compounds in new organisms or environmental samples. Natural Product Domain Seeker, NaPDoS [43] , a sequence-based phylogenetic classifier of PKS-I ketosynthase domains and NRPS condensation domains, is a move in this direction.
Experimental '-omics' tools such as transcriptomics, proteomics, and metabolomics are beginning to be applied to discovery of natural products and the gene clusters that encode them. These approaches have the advantage that they detect only transcriptionally active gene clusters and their downstream protein and metabolite products. A transcriptome mining approach [44] was used to discover previously unknown biosynthesis of four ansamycin class compounds in Streptomyces flaveolus, a strain whose genome had not been sequenced. A cDNA library from S. flaveolus was probed by PCR for PKS-I and NRPS-encoding cDNAs. Amplicon sequencing, gene disruption, and metabolite HPLC profiling of mutants led to identification of the compounds and their encoding gene cluster.
Another example [45] involves the discovery of the novel non-ribosomal peptide koranimine from an environmental Bacillus species using direct peptide sequencing tandem mass spectrometry of high molecular weight protein bands of PKS-I and NRPS. The resulting peptide sequences were used to identify the gene cluster which was then sequenced and analyzed in order to predict the structure of the encoded compound which was confirmed to be koranimine by small molecule mass spectrometry.
Finally, the therapeutically promising antibacterial agent arylomycin A2 was identified in Streptomyces roseosporus using an innovative combined imaging mass spectrometry (IMS)/short sequence tagging (SST) strategy [46 ] . S. roseosporus, whose genome has been sequenced, was spotted onto lawns of S. aureus and Staphylococcus epidermidis. IMS, a mass spectrometric technique that spatiotemporally detects intact masses of small molecules produced by a bacterial colony, was used to identify natural product ions associated with zones of inhibition. Mass fragmentation patterns of the molecules provided short sequence tags that, together with bioinformatics analysis, unambiguously identified the NRPS gene cluster encoding the compound and led to its structural assignment as that of arylomycin A2.
Most antibacterial natural products and their gene clusters studied thus far are from Actinobacteria, although Cyanobacteria, Proteobacteria, Firmicutes, and Fungi have emerged as additional sources. However, because many of these organisms grow slowly and are difficult to manipulate genetically, heterologous production of natural products in laboratory strains such as Escherichia coli would be advantageous. The marked differences in codon usage, gene regulation, levels of precursor metabolites, and compound self-resistance between most producing organisms and E. coli are so great that heterologous expression is extremely challenging [47] . Successful examples, such as those described above, are typically limited to small gene clusters that use ubiquitous precursors, and/or involve both optimizing gene expression and increasing precursor supplies by engineering. Successful heterologous expression of two out of ten natural product gene clusters from the closely related g-proteobacterium Photorhabdus luminescens in non-metabolically engineered E. coli was recently achieved [48] . The 80% attrition rate was attributed to toxicity and/or lack of expression. Steps toward optimizing E. coli for production of polyketide compounds by heterologous expression of pathways for key precursors propionyl-CoA and methylmalonyl-CoA, which are absent in wild-type E. coli, were successful, resulting in intracellular levels comparable to endogenous acyl-CoAs [49] . Advances in metabolic engineering and the decreasing cost of gene synthesis suggest that production of a variety of natural products in laboratory strains such as E. coli will soon become a reality.
Conclusions and future perspectives
Some of the early antibacterials originated from synthetic chemistry (e.g., dye research), as embodied by sulfa drugs, in the early 1930s. Indeed, some of these are among the most widely used bactericidal (e.g., quinolones) and bacteriostatic (e.g., sulfonamides) compounds. However, innovation in natural products research remains the main driver in antibiotic discovery. Since the introduction of antibiotics, we have witnessed advances in a variety of scientific fields and concurrent appearance of changes in the global socioeconomic environment that have led to complex clinical problems such as the emergence of bacterial multidrug resistance. Effective countermeasures to this adaptive response are not trivial and there is certainly no single solution to the problem. This article highlights the prominent role that innovation in natural products research continues to play in antibacterial drug discovery. Some compounds discussed here are closer to the bench while others are closer to the bedside. Yet acute sensitively on the part of regulatory and funding agencies to public health needs is essential for robust and timely clinical implementation of new therapies.
